Portal de Periódicos da CAPES

Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

2021; Nature Portfolio; Volume: 2; Issue: 12 Linguagem: Inglês

10.1038/s43018-021-00275-9

2662-1347

Annika Fendler, Lewis Au, Scott T.C. Shepherd, Fiona Byrne, Maddalena Cerrone, Laura Amanda Boos, Karolina Rzeniewicz, William Gordon, Benjamin Shum, Camille L. Gérard, Sophia Ward, Wenyi Xie, Andreas M. Schmitt, Nalinie Joharatnam‐Hogan, Georgina H. Cornish, Martin Pulé, Leila Mekkaoui, Kevin W. Ng, Eleanor Carlyle, Kim Edmonds, Lyra Del Rosario, Sarah Sarker, Karla Lingard, Mary Mangwende, Lucy Holt, Hamid Ahmod, Richard Stone, Camila Gomes, Helen R. Flynn, Ana Agua‐Doce, Philip Hobson, Simon Caidan, Michael Howell, Mary Wu, Robert Goldstone, Margaret Crawford, Laura Cubitt, Harshil Patel, Mike Gavrielides, Emma Nye, Ambrosius P. Snijders, James I. MacRae, Jérôme Nicod, Firza Alexander Gronthoud, Robyn Shea, Christina Messiou, David Cunningham, Ian Chau, Naureen Starling, Nicholas C. Turner, Liam Welsh, Nicholas van As, Robin L. Jones, Joanne Droney, Susana Banerjee, Kate Tatham, Shaman Jhanji, Mary O’Brien, Olivia Curtis, Kevin J. Harrington, Shreerang Bhide, Jessica Bazin, Anna Robinson, Clemency Stephenson, Tim Slattery, Yasir Khan, Zayd Tippu, Isla Leslie, Spyridon Gennatas, Alicia Okines, Alison Reid, Kate Young, Andrew J.S. Furness, Lisa Pickering, Sonia Gandhi, S.J. Gamblin, Charles Swanton, Emma Nicholson, Sacheen Kumar, Nadia Yousaf, Katalin A. Wilkinson, Anthony J. Swerdlow, Ruth Harvey, George Kassiotis, James Larkin, Robert J. Wilkinson, Samra Turajlic,

SARS-CoV-2 and COVID-19 Research

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4